GLP-1 RA treatment has been reported to increase irisin levels in patients with obesity and T2D
GLP-1RAs are a relatively new class of injectables that are effective at reducing HbA 1c , have a low risk of hypoglycaemia when given as monotherapy or in the absence of sulphonylureas (SU) or insulin, and have the potential for weight losskey considerations when treating a typical obese patient with T2DM [4]
CrossRef Development of a machine learning-based noninvasive diagnostic model for liver fibrosis in metabolic-associated steatotic liver disease Yixin Hui, Yuping Zeng, Mei Zhang European Journal of Gastroenterology & Hepatology .2026;[Epub] CrossRef Body Mass Index and Mucosal Healing in Japanese Patients with Ulcerative Colitis: A Cross-Sectional Study Masakazu Hanayama, Shinya Furukawa, Teruki Miyake, Osamu Yoshida, Hironubu Nakaguchi, Ayumi Kanamoto, Masumi Miyazaki, Yoshimasa Murakami, Keiichiro Horiuchi, Kazuhiro Tange, Shogo Kitahata, Tomoyuki Ninomiya, Seiyuu Suzuki, Katsuhisa Ohashi, Hideomi Tomi Digestion .2026
I used to find it difficult to resist snacking in the evenings, they noted
While factors predicting persistently high HbA1c levels have been studied in the type 2 diabetes population, similar studies in the type 1 diabetes (T1D) population looking at predictors of persistently and severely elevated HbA1c are lacking
Vital signs, including systolic and diastolic blood pressure and pulse rate, were summarized by treatment and presented as mean standard deviation (SD) changes from baseline
